TheEdgeResearch
Home / Stocks / CERT

Certara, Inc. (CERT)

NASDAQ Healthcare Medical - Healthcare Information Services
$9.11 ▲ +2.47%
Market Cap
$1.42B
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Beta
1.41
52-Wk Range
4.45-13.88
CEO
Jon Resnick
Country
US
Currency
USD

Certara, Inc. operates in the Medical - Healthcare Information Services industry of the Healthcare sector, headquartered in Radnor, PA, US. The stock last traded at $9.11, up 2.47% on the session, giving a market capitalisation of $1.42B. On trailing twelve-month figures it carries a trailing P/E of -20.55, a net margin of -16.7%. Its beta of 1.41 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-20.55
Price / Sales
3.47
Price / Book
1.45
EV / EBITDA
18.31
Gross margin
58.3%
Operating margin
1.9%
Net margin
-16.7%
Return on equity
—
Debt / equity
0.30
Current ratio
2.55
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Select
Employees
1,546
IPO date
2020-12-11
Headquarters
Radnor, PA, US
About Certara, Inc.

Certara, Inc. provides advanced software solutions and technology-driven services, specializing in biosimulation throughout the entire drug development lifecycle. From initial drug discovery and preclinical research to clinical trials, regulatory submissions, and market entry, the company's core mission is to accelerate the delivery of new medicines to patients by transforming these processes with its innovative biosimulation software and expertise. Its extensive portfolio of technology-enabled services includes mechanistic and empirical biosimulation, strategic guidance for drug development and regulatory affairs, clinical pharmacology, model-based meta-analysis, specialized regulatory writing and medical communications, regulatory operations support, and market access consultation. Furthermore, Certara offers a robust suite of software platforms covering mechanistic and empirical PK/PD biosimulation, data standardization and compliance, scientific informatics, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions, and market access communication. The company's clientele primarily comprises biopharmaceutical firms, academic institutions, and governmental organizations. Established in 2008 and headquartered in Princeton, New Jersey, Certara maintains a significant global presence, with operations spanning numerous countries including the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China.

Comparable companies

Certara, Inc. is most often compared with the following Healthcare names:

AVAHCLOVNHCOMCLPGNYQDELSDGRTWSTTXGVCEL
More research on CERT
CERT technical analysis CERT TheEdge Score Compare against peers
Open full interactive analysis & DCF →